Core Laboratories Inc. $CLB Shares Sold by T. Rowe Price Investment Management Inc.

Key Points

• T. Rowe Price Investment Management Inc. reduced its stake in Core Laboratories by 5.2%, now owning approximately 2.34% of the company, valued at around $16.47 million.
• Core Laboratories recently announced a quarterly dividend of $0.01 per share, with an ex-dividend date set for August 4th and an annualized yield of 0.4%.
• Despite a slight decline in revenue year-over-year, the company reported an EPS of $0.19, exceeding expectations, and has forecasted an EPS between 0.180-0.220 for Q3 2025.

T. Rowe Price Investment Management Inc. lowered its holdings in Core Laboratories Inc. (NYSE:CLB - Free Report) by 5.2% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,098,628 shares of the oil and gas company's stock after selling 60,074 shares during the period. T. Rowe Price Investment Management Inc. owned 2.34% of Core Laboratories worth $16,469,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Millennium Management LLC grew its position in shares of Core Laboratories by 429.0% in the fourth quarter. Millennium Management LLC now owns 65,616 shares of the oil and gas company's stock valued at $1,136,000 after purchasing an additional 53,213 shares during the period. Oppenheimer Asset Management Inc. increased its stake in Core Laboratories by 19.8% during the first quarter. Oppenheimer Asset Management Inc. now owns 69,184 shares of the oil and gas company's stock worth $1,037,000 after acquiring an additional 11,438 shares during the last quarter. Assetmark Inc. increased its stake in Core Laboratories by 92.5% during the first quarter. Assetmark Inc. now owns 2,887 shares of the oil and gas company's stock worth $43,000 after acquiring an additional 1,387 shares during the last quarter. Northern Trust Corp increased its stake in Core Laboratories by 15.6% during the fourth quarter. Northern Trust Corp now owns 577,752 shares of the oil and gas company's stock worth $10,001,000 after acquiring an additional 78,173 shares during the last quarter. Finally, Envestnet Asset Management Inc. increased its stake in Core Laboratories by 1.3% during the first quarter. Envestnet Asset Management Inc. now owns 254,005 shares of the oil and gas company's stock worth $3,808,000 after acquiring an additional 3,357 shares during the last quarter. Hedge funds and other institutional investors own 97.81% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have commented on the company. Wall Street Zen upgraded Core Laboratories from a "sell" rating to a "hold" rating in a research note on Saturday, July 26th. Stifel Nicolaus dropped their price target on Core Laboratories from $13.00 to $12.00 and set a "hold" rating for the company in a research note on Wednesday, July 16th. Zacks Research upgraded Core Laboratories from a "strong sell" rating to a "hold" rating in a research note on Friday, August 15th. Finally, Citigroup dropped their price target on Core Laboratories from $16.00 to $13.00 and set a "neutral" rating for the company in a research note on Tuesday, May 13th. Three investment analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, Core Laboratories currently has a consensus rating of "Hold" and an average target price of $12.50.

Core Laboratories Stock Up 1.6%

Shares of NYSE CLB traded up $0.18 on Thursday, hitting $11.32. The company had a trading volume of 380,480 shares, compared to its average volume of 456,719. Core Laboratories Inc. has a 12-month low of $9.72 and a 12-month high of $21.83. The business has a 50 day moving average of $11.49 and a two-hundred day moving average of $12.67. The company has a quick ratio of 1.70, a current ratio of 2.27 and a debt-to-equity ratio of 0.47. The firm has a market capitalization of $530.56 million, a P/E ratio of 18.25, a PEG ratio of 3.36 and a beta of 1.41.

Core Laboratories (NYSE:CLB - Get Free Report) last released its quarterly earnings results on Wednesday, July 23rd. The oil and gas company reported $0.19 EPS for the quarter, topping the consensus estimate of $0.18 by $0.01. The business had revenue of $130.16 million for the quarter, compared to analysts' expectations of $129.19 million. Core Laboratories had a return on equity of 14.15% and a net margin of 5.73%.The company's revenue was down .3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.22 earnings per share. Core Laboratories has set its Q3 2025 guidance at 0.180-0.220 EPS. As a group, equities research analysts forecast that Core Laboratories Inc. will post 0.96 earnings per share for the current fiscal year.

Core Laboratories Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, August 25th. Investors of record on Monday, August 4th were issued a $0.01 dividend. The ex-dividend date of this dividend was Monday, August 4th. This represents a $0.04 dividend on an annualized basis and a yield of 0.4%. Core Laboratories's dividend payout ratio is currently 6.45%.

Core Laboratories Company Profile

Core Laboratories Inc provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, and internationally. It operates through Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock and reservoir fluid samples to enhance production and improve recovery of crude oil and gas from its clients' reservoirs.